Rocket Companies Receives Buy Rating with $25 Price Target from Jefferies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 04 2026
0mins
Source: Benzinga
- Analyst Attention: Rocket Companies garnered significant investor interest this week as Jefferies initiated coverage with a Buy rating and a price target of $25, reflecting market confidence in its future growth prospects.
- Market Outlook: With increasing housing demand and lower rates expected in 2026, Rocket is poised to benefit, further solidifying its position in the mortgage sector.
- Contract Win: Sidus Space recently secured a new contract for the Missile Defense Agency's SHIELD program, enhancing its visibility in the space and defense sector, which contributed to a rise in its stock price, indicating investor confidence in its growth potential.
- IPO Performance: Medline Inc went public on December 17, pricing its IPO at $29 and trading up over 40% to $41 on its first day, demonstrating strong market demand for its medical products and positive investor sentiment.
Analyst Views on MDLN
Wall Street analysts forecast MDLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDLN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 43.410
Low
Averages
High
Current: 43.410
Low
Averages
High
No data
About MDLN
Medline Inc. is a provider of medical-surgical products and supply chain solutions serving all points of care. The Company delivers mission-critical products used daily across the full range of care settings, from hospitals and surgery centers to physician offices and post-acute facilities. It operates through two segments: Medline Brand and Supply Chain Solutions. These segments offer approximately 335,000 medical-surgical products, including surgical and procedural kits, gloves and protective apparel, urological and incontinence care, wound care, and consumable lab and diagnostics products. Its Medline Brand products are organized into three product categories: Front Line Care, Surgical Solutions, and Laboratory and Diagnostics. The Supply Chain Solutions segment procures and distributes a variety of third-party products from national brands and also provides tailored logistics and supply chain optimization services to domestic and international consumers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
